Puncture (Shanghai) Robotic Co., Ltd (“Puncture”) recently has announced the completion of the Series A++ funding of hundred millions CNY.
Puncture is a research and development company for fusion imaging navigation surgical robots, providing professional solutions for clinical common needs. The product pipeline covers both serious medical and consumer medical fields, and several robot products have been developed for clinical applications such as puncture, tumor intervention therapy, biopsy, anesthesia, and medical aesthetics. The company is committed to creating better equipment and conditions for medical services, allowing high-end technology to serve all humanity.
According to Puncture, its core product HAIRO ® Hair transplant robots recognize hair through stereo vision positioning technology and use algorithmic planning to control robotic arms to complete hair follicle extraction surgery. The hair follicle cross-sectional rate is reduced compared to manual surgery, and innovative minimally invasive needle type trauma is smaller, achieving a hidden scar effect while effectively shortening the recovery cycle.
According to Mordor Intelligence, the global surgical robot market size was USD 4.437 billion in 2020, and it is expected to reach USD 9.592 billion by 2026, with a compound annual growth rate of 11.4%. This growth is driven by increasing demand for surgery, the increasing demand for automation in the medical industry, and the complexity of surgical procedures.
In addition to Puncture, many companies are competing in the surgical robot market, such as HOZ Medical (华志微创), Remebot (柏惠维康), Weigao Holding (威高股份), Microport (微创医疗) and Define Vascular Operation (奥朋医疗) in China, Intuitive Surgical Co., Stryker Corporation and Accuray Incorporated in the United States, and CMR Surgical, Renishaw PLC in England.
Jingjing Yan, Partner of Probe Capital, stated: “Despite the pressure of the epidemic, the demand for hair transplantation is still increasing in China, and we are very optimistic about this direction of consumer healthcare. Robots are naturally suitable for hair transplantation scenarios, greatly optimizing existing human hair transplantation in terms of efficiency, quality, and cost. After years of polishing, Puncture's hair transplantation robots have become the most advanced among domestic hair transplant robots. We are confident in the technology and ultimate certification of robots for multi body experiments. We believe that Puncture will become the leading hair transplant robot company in China in the future.”
This round of financing for Puncture was exclusively invested by HNDY Capital (华鼎投资). Probe Capital (探针资本) acted as the financial advisor. This round of funds will mainly be used for clinical certification, capacity enhancement, and global promotion, comprehensively accelerating the arrival of the global intelligent era.